Beta thalassemia is blood disorder caused by sequent variants in the beta-globin (HBB) gene that threaten normal production of hemoglobin. Lentiviral Autologous Beta-Globin Gene Therapy (Proposed Name: Zynteglo, formerly LentiGlobin) aims to reduce or eliminate the need for regular blood transfusions in patients with transfusion-dependent beta-thalassemia by replacing the faulty HBB gene in the patient’s DNA with a healthier copy of the gene.

If you have a Hayes login, click here to view the full report on the Knowledge Center.